Becker's Healthcare January 14, 2025
Alexandra Murphy

Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13.

The company is preparing to release key late-stage trial data on the drug by mid-2025. The weight loss pill aims to compete with popular injectable treatments like Eli Lilly’s own Zepbound and Novo...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Pharma / Biotech
Fast-Tracking Development: How Life Sciences Will Drive Speed in 2025
How Technology is Impacting Launch Strategy Timelines
mRNA Vaccine Shows Promise In Pancreatic Cancer Trial
Hims & Hers vs. Novo Nordisk: Are Compounded GLP-1s Safe?
On Heels of FDA Nod, BridgeBio’s Rival to Blockbuster Pfizer Drug Wins European Approval

Share This Article